/ALVO
ALVO Stock - Alvotech
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$4.90+3.59%
+$0.17 (+3.59%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+93.9%upside
Target: $9.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.85 – $4.95
TARGET (TP)$9.50
STOP LOSS$4.51
RISK/REWARD1:11.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.13
52W High$13.70
52W Low$4.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $489.68M | $91.43M | $83.03M | $36.77M | $66.62M |
| Gross Profit | $304.37M | $-69,422,000 | $18.93M | $36.77M | $66.62M |
| Gross Margin | 62.2% | -75.9% | 22.8% | 100.0% | 100.0% |
| Operating Income | $69.64M | $-354,860,000 | $-346,442,000 | $-235,456,000 | $-137,537,000 |
| Net Income | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 | $-170,044,000 |
| Net Margin | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% |
| EPS | $-0.87 | $-2.43 | $-2.60 | $-3.25 | $-5.44 |
Company Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
40%
Hold / Neutral
5
50%
Sell / Underperform
1
10%
Analyst Consensus🔴 Bearish
4 Bullish6 Neutral/Bearish
Price Targets
$12
Average Target
↑ 141.8% Upside
Now
$5
Low
$12
Average
$21
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Underweight | $5 |
| November 4th 2025 | Deutsche Bank | Downgrade | Hold | $8 |
| October 14th 2025 | Morgan Stanley | Upgrade | Overweight | $14 |
| September 23rd 2025 | Deutsche Bank | Upgrade | Buy | $14 |
| February 14th 2025 | UBS | Initiation | Buy | $18 |
| January 29th 2024 | Barclays | Upgrade | Overweight | $17← $10 |
| October 20th 2023 | Citigroup | Upgrade | Neutral | $10← $5 |
| September 21st 2023 | Barclays | Initiation | Equal Weight | $10 |
| September 7th 2022 | Morgan Stanley | Initiation | Equal Weight | $10 |
| September 6th 2022 | Citigroup | Downgrade | Sell | $5← $12 |
| July 26th 2022 | Citigroup | Initiation | Buy | $12 |
| July 1st 2022 | Deutsche Bank | Initiation | Hold | $10 |
| June 29th 2022 | DNB Markets | Initiation | Buy | $21 |
Earnings History & Surprises
ALVOBeat Rate
50%
Last 10 quarters
Avg Surprise
-131.6%
EPS vs Estimate
Beats / Misses
5/5
Last 12 quarters
Latest EPS
$-0.02
Q4 2025
EPS Surprise History
Q1 24
-913.3%
$-1.22vs$0.15
Q2 24
-972.3%
$-0.89vs$-0.08
Q3 24
+200.0%
$0.28vs$-0.28
Q4 24
+401.6%
$0.19vs$-0.06
Q1 25
+38.5%
$-0.24vs$-0.39
Q2 25
+305.9%
$0.35vs$-0.17
Q3 25
+153.8%
$0.14vs$-0.26
Q4 25
-140.0%
$-0.02vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $0.13 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.05 | $-0.02 | -140.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.26 | $0.14 | +153.8% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.17 | $0.35 | +305.9% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.39 | $-0.24 | +38.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.06 | $0.19 | +401.6% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-0.28 | $0.28 | +200.0% | ✓ BEAT |
Q2 2024 | May 21, 2024 | $-0.08 | $-0.89 | -972.3% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $0.15 | $-1.22 | -913.3% | ✗ MISS |
Q4 2023 | Nov 28, 2023 | $-0.29 | $-0.82 | -182.8% | ✗ MISS |
Q3 2023 | Aug 30, 2023 | $-0.14 | $-0.43 | -207.1% | ✗ MISS |
Q2 2023 | May 19, 2023 | — | $-0.33 | — | — |
Q1 2023 | Mar 1, 2023 | — | $-1.29 | — | — |
Q4 2022 | Nov 16, 2022 | — | $-0.04 | — | — |
Q3 2022 | Sep 1, 2022 | — | $-0.54 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.32 | — | — |
Q1 2022 | Mar 30, 2022 | — | $1.28 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.41 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 20, 2021 | — | $0.23 | — | — |
Latest News
Alvotech And Teva Reach US Settlement With Regeneron For AVT06 Proposed Biosimilar To Eylea Setting License Entry In Q4 2026
📈 PositiveBenzinga•Dec 19, 2025, 08:45 AM•Also: ,
Alvotech Reaffirms FY25 Guidance; Sees FY25 Revenue $570M-$600M; Sees Adj. EBITDA $130M-$150M; Sees FY26 Revenue $650M-$700M
📈 PositiveBenzinga•Dec 17, 2025, 01:41 PM
Barclays Initiates Coverage On Alvotech with Underweight Rating, Announces Price Target of $5
📉 NegativeBenzinga•Dec 9, 2025, 03:16 PM•Also:
Alvotech Wins EU Green Light For Cancer-Related Bone Treatment Alternative
📈 PositiveBenzinga•Nov 24, 2025, 10:31 AM
Alvotech And Advanz Pharma Announce EEA Approval For Gobivaz Biosimilar To Simponi Strengthening Access To High Quality Biologic Medicines
📈 PositiveBenzinga•Nov 20, 2025, 09:08 AM
UBS Maintains Buy on Alvotech, Lowers Price Target to $10
➖ NeutralBenzinga•Nov 18, 2025, 07:00 PM•Also:
Alvotech Lowers FY2025 Sales Guidance from $600.000M-$700.000M to $570.000M-$600.000M vs $592.949M Est
📉 NegativeBenzinga•Nov 12, 2025, 10:01 PM
Alvotech Q3 EPS $(0.02), Inline, Sales $113.744M Miss $117.203M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 10:00 PM
Alvotech Secures Legal Victory In UK Supporting Manufacturing Freedom And Market Access For AVT06 Biosimilar To Eylea
📈 PositiveBenzinga•Nov 10, 2025, 09:36 AM
Alvotech And Advanz Pharma Receive UK MHRA Approval For Gobivaz Biosimilar Across Multiple Indications
📈 PositiveBenzinga•Nov 6, 2025, 02:15 PM
Deutsche Bank Downgrades Alvotech to Hold, Lowers Price Target to $8
📉 NegativeBenzinga•Nov 4, 2025, 10:54 AM•Also:
ALVO stock has given up its prior gain. Alvotech shares were trading higher after the company received an FDA Complete Response Letter for its AVT05 biosimilar application and revised its 2025 outlook amid facility-related investments.
📉 NegativeBenzinga•Nov 3, 2025, 12:28 PM
Alvotech shares are trading higher after the company received an FDA Complete Response Letter for its AVT05 biosimilar application and revised its 2025 outlook amid facility-related investments.
📈 PositiveBenzinga•Nov 3, 2025, 11:58 AM
Alvotech stock slides as FDA issues CRL for AVT05, company cuts EBITDA outlook
📉 NegativeSeeking Alpha•Nov 3, 2025, 10:20 AM
Reported Sunday, Alvotech Announces FDA Complete Response Letter For AVT05 Biosimilar Application And Revises 2025 Outlook Amid Facility-Related Investments
📉 NegativeBenzinga•Nov 3, 2025, 07:52 AM
Morgan Stanley Upgrades Alvotech to Overweight, Announces $14 Price Target
📈 PositiveBenzinga•Oct 14, 2025, 12:54 PM
2. Advanz Pharma, Alvotech Move Closer To Launching Affordable Asthma And Allergy Treatment In Europe After EMA Filing Acceptance
📈 PositiveBenzinga•Oct 6, 2025, 08:45 AM
Alvotech shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy.
📈 PositiveBenzinga•Sep 23, 2025, 07:51 PM•Also:
Deutsche Bank Upgrades Alvotech to Buy, Announces $14 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 12:42 PM•Also:
Alvotech Wins EU Panel Backing For Biosimilar To Prolia And Xgeva, Expanding Affordable Bone Disease Treatments
📈 PositiveBenzinga•Sep 22, 2025, 10:20 AM
Frequently Asked Questions about ALVO
What is ALVO's current stock price?
Alvotech (ALVO) is currently trading at $4.90 per share. The stock has moved +3.59% today.
What is the analyst price target for ALVO?
The average analyst price target for ALVO is $9.50, based on 1 analyst.
What sector is Alvotech in?
Alvotech operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ALVO's market cap?
Alvotech has a market capitalization of $1.53 billion, making it a small-cap company.
Does ALVO pay dividends?
No, Alvotech does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
COLL
Collegium Pharmaceutical, Inc.
$48.88
Mkt Cap: $1.5B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
HROW
Harrow Health, Inc.
$46.40
Mkt Cap: $1.7B
PAHC
Phibro Animal Health Corporation
$37.25
Mkt Cap: $1.5B
PGNY
Progyny, Inc.
$26.63
Mkt Cap: $2.3B
SEM
Select Medical Holdings Corporation
$15.01
Mkt Cap: $1.9B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
UFPT
UFP Technologies, Inc.
$229.40
Mkt Cap: $1.8B
Explore stocks similar to ALVO for comparison